Updated from 2:26 p.m. EDTShares of Cardiac Science ( DFIB) were among the worst-performing health and pharmaceutical stocks Friday after the company posted second-quarter results that missed expectations and warned that third-quarter results would fall below expectations as well. The maker of defibrillators posted a loss of 7 cents a share on sales of $17.5 million. Analysts polled by Thomson First Call had expected it to post a loss of 4 cents a share on sales of $17.5 million. Looking ahead, it expects to report a third-quarter loss of 4 cents to 6 cents a share, wider than the loss of 2 cents a share analysts had been expecting. Sales, meanwhile, are now expected to be $16.5 million to $18.5 million. Analysts were looking for $18.8 million. Shares of Cardiac Science traded down 85 cents, or 29.6%, to $2.02. Viasys Healthcare ( VAS) fell after it reported weaker-than-expected second-quarter earnings. Excluding items, the health care technology company posted earnings of 13 cents a share on sales of $95.4 million. Analysts had expected it to earn 22 cents a share on sales of $104.7 million. Looking ahead, the company said that first- and second-quarter results lead it to believe that full-year earnings and sales will be equal to results from 2003. Shares of Viasys Healthcare traded down $3.48, or 18.7%, to $15.15. Shares of Gilead Sciences ( GILD) rose after the company reported blowout second-quarter earnings and sales. The biotech company posted earnings of 49 cents a share on sales of $319.7 million. Analysts had predicted that it would earn 36 cents a share on sales of $285.8 million. A year ago it earned 46 cents a share on sales of $238.9 million. Shares of Gilead Sciences traded up $5.14, or 8.6%, to $64.64. Staar Surgical ( STAA) fell after it reported weaker-than-expected second-quarter earnings and sales and warned that full-year results would fall short of expectations. The medical device maker posted a second-quarter loss of 18 cents a share on sales of $12 million. Analysts had expected a smaller loss of 7 cents a share on sales of $13.8 million. Looking ahead, Staar expects a full-year loss of 52 cents to 55 cents a share, substantially higher than the loss of 20 cents that analysts were expecting. Shares of Staar Surgical traded down 72 cents, or 12%, to $5.29.